Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Ankyra Therapeutics logo — Developing cancer therapies based on localized cytokines tha...

Ankyra Therapeutics

Developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response

Founded 2019 23 employees Series B Total: $59.50M Biotechnology

General Information

Company Name Ankyra Therapeutics
Founded Year 2019
Founders / Decision Makers
Team member Team member
Employees 23
Industries Biotechnology
Funding Stage Series B
Social

Get notified when Ankyra Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Ankyra Therapeutics

Ankyra Therapeutics is a biotechnology startup founded in 2019 with a vision to revolutionize cancer treatment. The company's flagship approach, coined as Anchored Immunotherapy, aims to harness the power of localized cytokines to trigger a systemic adaptive immune response, holding the potential to combat cancer with minimal systemic toxicity. With its recent $45.00M Series B investment on 12 November 2021, Ankyra has garnered support from prominent investors including GV, Mithril Capital, Polaris Partners, Spring Mountain Capital, Borealis Ventures, Sands Capital Ventures, and Fidelity. This substantial financial backing signifies not only the market's confidence in Ankyra's breakthrough cancer therapy but also the recognition of its innovative potential in the biotechnology landscape.

Taxonomy: cancer therapy, immunotherapy, localized cytokines, adaptive immune response, Anchored Immunotherapy, immune activation, systemic toxicity, oncology, tumor microenvironment, immune modulation, clinical trials, precision medicine

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Series B •••••• 7
Investor Investor Investor Investor Investor Investor Investor
12 Nov 2021
Seed Round •••••• 1
Investor
16 May 2020

Ankyra Therapeutics Alternatives & Competitors

Ankyra Therapeutics vs
ImmunoCellular Therapeutics Ltd
ImmunoCellular Therapeutics Ltd United States

Pioneering immune-based therapies to harness the body's defenses against cancer through advanced imm...

Grant
11 employees
Biotechnology, Health Care
Ankyra Therapeutics vs
Inimex Pharmaceuticals
Inimex Pharmaceuticals

Advancing health by harnessing the body's natural defenses with innovative, non-inflammatory therapi...

Series B
Biotechnology, Pharmaceutical
Ankyra Therapeutics vs
Emergo Therapeutics
Emergo Therapeutics United States

Bringing the Immune Response Back into Balance

Series Unknown
5 employees
Biopharma, Biotechnology

FAQ About Ankyra Therapeutics

Developing cancer therapies based on localized cytokines that prime a systemic adaptive immune response
Ankyra Therapeutics was founded in 2019.
Ankyra Therapeutics operates in the following industries: Biotechnology.
Ankyra Therapeutics has approximately 23 employees.
Ankyra Therapeutics has completed 2 funding rounds, raising a total of $59.50M. The latest funding stage is Series B.
Top alternatives and competitors to Ankyra Therapeutics include ImmunoCellular Therapeutics Ltd, Inimex Pharmaceuticals, Emergo Therapeutics, Tolerx, Inc., Georgiamune Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ankyra Therapeutics and ImmunoCellular Therapeutics Ltd are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Ankyra Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes